IGFBP-1 ELISA
- Regulatory Status
- RUO
- Incubation time
- 1x 1h; 1 x 30min; 1x 15 min
- Kit size
- 12 x 8
- Specimen / Volumes
- 20µL serum, plasma
- Standard range
- 0 – 128 ng/mL
- Substrate / isotope
- TMB 450 nm
| instructions for use |
|---|
IGFBP-1 ELISA
Intended use
This enzyme immunoassay kit is for research use only and measures IGFBP-1 in human serum or Heparin and EDTA plasma or in other body fluids, for example amnion fluid, mother milk, urine or saliva. It is also suited to quantify IGFBP-1 in cell culture media.
Introduction
The Insulin-like Growth Factors I and – II are free in body fluids and tissues but are bound to specific binding proteins. Until today seven different binding proteins (IGFBP-1 to –7) can be differentiated additionally several IGFBP-related proteins have also been detected. Bioavailability of IGF is regulated by these IGFBPs or better their proteolytic cleavage which reduces affinity to IGF. But the IGFBPs as well as their proteolytic fragments can also exert IGF-independent effects, like influencing cell migration or proliferation. IGFBP-1 (Placental Protein 12) consists of 234 amino acids and has a molecular weight of approximately 25kDa. The coding DNA region is located on chromosome 7. IGFBP-1 is mainly synthesized by foetal and adult liver tissue and decidual endometrium. Intensity of Expression varies enduring menstruation with a maximal expression in the late secretory phase. IGFBP-1 is posttranslational modified by phosphorylation of serine residues 101, 119 and 169. Phosphorylation has physiological relevance as it increases affinity of IGFBP-1 to IGF. In adult humans phosphorylated IGFBP-1 of the liver is the predominant form in circulation. IGFBP-1 produced by endometrial tissue is significantly less phosphorylated than the liver originated form
For concrete data please consult the Instruction for Use in the download box on the top right side.
1. Rechler, M.M., Insulin-like growth factor binding proteins. Vitam Horm, 1993. 47: p. 1- 114.
2. Allander, S.V., et al., Structure and chromosomal localization of human insulin-like growth factor-binding protein genes. Growth Regul, 1993. 3(1): p. 3-5.
3. Rutanen, E.M., et al., Synthesis of placental protein 12 by human decidua. Endocrinology, 1985. 116(4): p. 1304-9.
4. Julkunen, M., et al., Identification by hybridization histochemistry of human endometrial cells expressing mRNAs encoding a uterine beta-lactoglobulin homologue and insulin-like growth factor-binding protein-1. Mol Endocrinol, 1990. 4(5): p. 700-7.
5. Khosravi, J., et al., Immunoassay of serine-phosphorylated isoform of insulin-like growth factor (IGF) binding protein (IGFBP)-1. Clin Biochem, 2007. 40(1-2): p. 86-93.
6. Westwood, M., Role of insulin-like growth factor binding protein 1 in human pregnancy. Rev Reprod, 1999. 4(3): p. 160-7.
7. Rutanen, E.M., H. Bohn, and M. SeVPala, Radioimmunoassay of placental protein 12: levels in amniotic fluid, cord blood, and serum of healthy adults, pregnant women, and patients with trophoblastic disease. Am J Obstet Gynecol, 1982. 144(4): p. 460-3.
8. Drop, S.L., et al., Immunoassay of a somatomedin-binding protein from human amniotic fluid: levels in fetal, neonatal, and adult sera. J Clin Endocrinol Metab, 1984. 59(5): p. 908-15.
9. Hall, K., G. Lundin, and G. Povoa, Serum levels of the low molecular weight form of insulin-like growth factor binding protein in healthy subjects and patients with growth hormone deficiency, acromegaly and anorexia nervosa. Acta Endocrinol (Copenh), 1988. 118(3): p. 321-6.
10. Busby, W.H., D.K. Snyder, and D.R. Clemmons, Radioimmunoassay of a 26,000- dalton plasma insulin-like growth factor-binding protein: control by nutritional variables. J Clin Endocrinol Metab, 1988. 67(6): p. 1225-30.
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.